TrialJournal for immunotherapy of cancer2025

Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trial.

Martin E Eichhorn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.